SMMT — Summit Therapeutics Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1599298 ·
Last close
$10.67
Market Cap
$8.53B
52W High
$29.23
52W Low
$10.53
ADV30
5,990,067
Next earnings
2026-11-04

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 0 — -214,611,000 -208,385,000 692,850,000 150,811,000 128,167,000
Jun 2026 0 — -220,496,000 -215,700,000 752,185,000 419,365,000 122,202,000
Mar 2026 0 — -195,212,000 -189,424,000 647,856,000 106,515,000 101,924,000
Dec 2025 0 — -224,875,000 -219,172,000 751,182,000 225,266,000 92,322,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-525,167,000
Investing CF
$-466,663,000
Financing CF
$904,128,000
CapEx
$-1,714,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.07
As of
2026-11-08

Balance + Analyst (yfinance extras)

Retained Earnings
$-2,907,668,000
Inventory
—
Receivables
—
ST Investments
$478,976,000
EBIT TTM
$-849,441,000
Pretax Income TTM
$-832,631,000
Interest Exp TTM
$0
Analysts
13

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -1,094,374,000 -1,079,586,000 751,182,000 92,322,000 658,860,000 -322,930,000
Dec 2024 0 -210,977,000 -221,315,000 435,560,000 46,812,000 388,748,000 -142,106,000
Dec 2023 0 -88,735,000 -614,928,000 202,949,000 125,257,000 77,692,000 -76,760,000
Dec 2022 705,000 -63,621,000 -78,782,000 664,168,000 537,514,000 126,654,000 -41,582,000

TTM Snapshot

Revenues TTM
—
NetIncome TTM
$-856,089,000
OpCashFlow TTM
—
Assets (Latest)
$752,185,000
Forward EPS
$-1.06

Max Pain — expiry 2026-12-18

max pain strike: $14.00 · spot: $10.50 · call oi: 2,808 · put oi: 2,316
Expected Move to 2026-12-18: ±$4.38 (41.67%) — implied range $6.12 – $14.88 · ATM straddle on $10.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
PRAX Praxis Precision Medicines, Inc. $8.53B $305.06 —
SYRE Spyre Therapeutics, Inc. $8.91B $93.81 —
RYTM RHYTHM PHARMACEUTICALS, INC. $8.08B $116.61 —
PTGX Protagonist Therapeutics, Inc $8.07B $124.67 —
TGTX TG THERAPEUTICS, INC. $9.48B $62.71 —

News headlines (Yahoo Finance, 1h cache)

FDA publishes rejection letter for Summit drug; Nuvalent buyout pays more dividends for GSK
2026-11-18 14:21 · Yahoo
Summit Therapeutics Further Expands Ivonescimab Global Development Program with Phase III HARMONi-10 Study in Unresectable Stage III Non-Small Cell Lung Cancer
2026-11-18 11:00 · Yahoo
Summit Therapeutics (SMMT) Is Losing Wall Street’s Confidence
2026-11-18 06:58 · Yahoo
Summit Therapeutics (SMMT) Stock Sees Modest Fair Value Cut As Analysts Weigh Trial Risks
2026-11-17 11:14 · Yahoo
Summit Therapeutics (SMMT) Hits 52-Week Low After FDA Setback
2026-11-17 02:20 · Yahoo
Summit Crumbles After FDA Rejects Merck-Rivaling Lung Cancer Drug
2026-11-16 21:27 · Yahoo
2 Cancer-Drug Developers Seeing Unusual Options Volume
2026-11-16 18:01 · Yahoo
Summit Therapeutics (SMMT) Faces An FDA Reset, Is The Downside Already Priced In?
2026-11-16 17:14 · Yahoo
Summit shares fall as FDA rejects closely watched PD-1/VEGF drug
2026-11-16 17:14 · Yahoo
AstraZeneca Bet $2 Billion on Summit’s Cancer Drug. The FDA Just Said Not Yet.
2026-11-16 16:37 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.